Aadi Bioscience Announces Participation in Upcoming September Investor Conferences

Rhea-AI Summary

Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focusing on precision therapies for cancers with mTOR pathway gene alterations, announced its participation in several September investor conferences. These include Citi's Annual BioPharma Conference (Sept 7-8), Morgan Stanley's Global Healthcare Conference (Sept 12-14), and H.C. Wainwright's Investment Conference (Sept 12-14) in New York. Founder and CEO Neil Desai will present and participate in discussions, with webcasts available on the company's website. Aadi continues to develop its pipeline after receiving FDA approval for FYARRO® in November 2021.

Positive

• Aadi's participation in multiple conferences may enhance investor visibility and engagement.
• Recent FDA approval of FYARRO® demonstrates the company's ability to advance its product offerings in the oncology sector.
• Commencement of the PRECISION 1 Phase 2 trial highlights ongoing development of innovative therapies.

Negative

• None.

LOS ANGELES, Sept. 1, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be participating in and hosting one-on-one meetings at the following conferences during September:

• Citi's 17^th Annual BioPharma Conference, September 7-8, 2022, in Boston, MA
• Morgan Stanley's 20^th Annual Global Healthcare Conference, September 12-14, 2022, in New York, NY
•  
• Neil Desai, Ph.D., Aadi Bioscience Founder and CEO, will take part in a 30-minute fireside chat on Wednesday, September 14^th at 2:55 pm ET
• A live webcast of the fireside chat will be available on the Investors & News page of the Company's website
• H.C. Wainwright's 24^th Annual Global Investment Conference, September 12-14, 2022, in New York, NY
•  
• A pre-recorded presentation will be available on the Investors & News page of the Company's website on Monday, September 12 at 7:00 am ET
• Ladenburg Thalmann's 2022 Healthcare Conference, September 29, 2022, in New York, NY
•  
• Neil Desai, Ph.D., Aadi Bioscience Founder and CEO, will give a brief presentation followed by an analyst-led fireside chat from 9:00 am – 9:25 am ET
• A live webcast of the presentation will be available on the Investors & News page of the Company's website

Replays of webcasts will be available for approximately 30 days following each presentation.

About Aadi Bioscience 

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022, Aadi announced the commercial launch of FYARRO in this indication.

Based on exploratory data from AMPECT, a registrational study supporting approval in advanced malignant PEComa, and following a pre-IND meeting with the FDA, Aadi has initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
Marcy Graham
IR@aadibio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-announces-participation-in-upcoming-september-investor-conferences-301615912.html

SOURCE Aadi Bioscience

FAQ

What conferences is Aadi Bioscience participating in September 2022?

Aadi Bioscience will participate in Citi's Annual BioPharma Conference (Sept 7-8), Morgan Stanley's Global Healthcare Conference (Sept 12-14), and H.C. Wainwright's Investment Conference (Sept 12-14).

Who is presenting for Aadi Bioscience at the upcoming conferences?

Neil Desai, Ph.D., Founder and CEO of Aadi Bioscience, will present and engage in fireside chats at the conferences.

What is the significance of Aadi's FDA approval for FYARRO®?

The FDA approval for FYARRO® marks a crucial milestone for Aadi, allowing them to provide treatment for patients with a specific type of cancer.

What is the PRECISION 1 trial initiated by Aadi Bioscience?

The PRECISION 1 trial is a Phase 2 registration-intended study focusing on mTOR inhibitor-naïve malignant solid tumors with specific genetic alterations.

Where can I find Aadi Bioscience's webcast presentations?

Webcast presentations will be available on the Investors & News page of Aadi Bioscience's website.